A pharmacoeconomic model of outpatient antipsychotic therapy in 'revolving door' schizophrenic patients

Journal of Clinical Psychiatry

Volumn 57, Issue 8, 1996, Pages 337-345

  Glazer, William M ^a   Ereshefsky, Larry ^b,c,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d MC 6220   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; RISPERIDONE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; PHARMACOECONOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; DELAYED-ACTION PREPARATIONS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; PATIENT COMPLIANCE; PATIENT READMISSION; PROBABILITY; QUALITY OF LIFE; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0029846685     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Wyatt RJ, Henter I, Leary MG, et al. An economic evaluation of schizophrenia: 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:196-205
2. Freund DA, Dittos PR. Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics 1992;1:20-32
3. Jaescke R, Guyatt GH, Cook D. Quality of life instruments in the evaluation of new drags. Pharmacoeconomics 1992;1:84-94
4. Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm 1992;49:1741-1747
5. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987;316: 250-258
6. Revicki DA, Luce BR. Pharmacoeconomics research applied to psychopharmacology development and evaluation. Psychopharmacol Bull 1995; 31:57-65
7. Eisenberg TM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989;262:2879-2886
8. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993;54(3, suppl):13-17
9. Caton CLM, Koh SP, Fleiss JL, et al. Rehospitalization in chronic schizophrenia. J Nerv Ment Dis 1985;173:139-148
10. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429
11. Davis JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry 1993;54(3, suppl):24-30
12. Davis JM, Metalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741-773
13. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992;53:426-433
14. Ereshefsky L, Toney G, Saklad SR, et al. A loading-dose strategy for converting from oral to depot neuroleptics. Hosp Community Psychiatry 1993;44:1155-1161
15. Ereshefsky L, Saklad SR, Tran-Johnson TJ, et al. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. Psychopharmacol Bull 1990;26:108-114
16. Weiden PJ, Dixon L, Frances A, et al. Neuroleptic noncompliance in schizophrenia. In: Tamminga CA, Schulz SC, eds. Advances in Neuropsychiatry and Psychopharmacology, vol 1: Schizophrenia Research. New York, NY: Raven Press; 1991:285-296
17. Jann MW, Ereshefsky L, Saklad SR. The pharmacokinetics of depot antipsychotics. Clin Pharmacokinet 1985;10:315-333
18. Pinard G, Rosales D. Rapid stabilization of fluphenazine dosage in the treatment of the acute exacerbation of schizophrenia. Curr Ther Res 1980; 27:419-428
19. Schooler NR, Levine J, Severe JB, NIMH-PRB Collaborative Study Group. Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen. Psychopharmacol Bull 1979;15:44-47
20. Schooler NR, Levine J, Severe JB, et al. Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry 1980;37:16-24
21. Johnson DAW, Pasterski JM, Ludlow JM, et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983;67:339-352
22. Yousef HA. A five-year follow-up study of chronic schizophrenics and other psychotics treated in the community: depot haloperidol decanoate versus other neuroleptics. Advances Therapy 1989;67:186-195
23. Ereshefsky L, Saklad SR, Jann MW, et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984:45(5, sec 2):50-59
24. Hogarty GE, Schooler NR, Ulrich R, et al, Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979;36:1238-1294
25. Hogarty GE, Anderson C, Reiss D, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia, II: two-year effects of a controlled study on relapse and adjustment. Arch Gen Psychiatry 1991;48:340-347
26. Hagen MD. Decision analysis: a review. Fam Med 1992;24:349-354
27. Weinstein MC. Utility analysis. In: Weinstein MC, Fineberg HV, eds. Clinical Decision Analysis. Philadelphia, Pa: Saunders; 1980:184-227
28. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38(suppl 2):S80-S88
29. Goldberg D. Cost-effectiveness studies in the treatment of schizophrenia: a review. Soc Psychiatry Psychiatr Epidemiol 1991;26:139-142